Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Graefes Arch Clin Exp Ophthalmol ; 262(6): 1745-1753, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38217767

RESUMEN

PURPOSE: This study aimed to evaluate anterior flare intensity (AFI) after intravitreal injection of brolucizumab (IVBr) in patients with diabetic macular edema (DME), and to identify the factors associated with the change of AFI after IVBr. METHODS: This prospective multicenter study was conducted at five sites in Japan for patients with DME who underwent a single IVBr. AFI and central retinal thickness (CRT) were measured using a laser flare meter and spectral-domain optical coherence tomography, respectively, at weeks 0 and 6. RESULTS: Sixty-five patients (phakia, 37 eyes; pseudophakia, 28 eyes) were enrolled. Six weeks after IVBr, CRT and best-corrected visual acuity significantly improved (p < 0.0001). AFI (p = 0.0003) and age (p = 0.0054) were significantly higher in patients with pseudophakic eyes than those with phakic eyes. The AFI of the phakic eyes decreased after IVBr (p = 0.043). As the AFI before injection is higher (p = 0.0363) and the age is lower (p = 0.0016), the AFI decreases after IVBr. There was a significant positive correlation between the rates of change in CRT and AFI (p = 0.024). CONCLUSION: After IVBr, AFI decreases in phakic eyes but not in pseudophakic eyes. The age, AFI and CRT before injection and changes of CRT are involved in the change in AFI after IVBr.


Asunto(s)
Inhibidores de la Angiogénesis , Anticuerpos Monoclonales Humanizados , Retinopatía Diabética , Inyecciones Intravítreas , Edema Macular , Tomografía de Coherencia Óptica , Agudeza Visual , Humanos , Edema Macular/diagnóstico , Edema Macular/tratamiento farmacológico , Edema Macular/etiología , Retinopatía Diabética/diagnóstico , Retinopatía Diabética/tratamiento farmacológico , Masculino , Tomografía de Coherencia Óptica/métodos , Femenino , Estudios Prospectivos , Inhibidores de la Angiogénesis/administración & dosificación , Persona de Mediana Edad , Anciano , Anticuerpos Monoclonales Humanizados/administración & dosificación , Anticuerpos Monoclonales Humanizados/efectos adversos , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Estudios de Seguimiento , Resultado del Tratamiento , Angiografía con Fluoresceína/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA